Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Cancer: Escape from inhibition.

Courtneidge SA.

Nature. 2003 Apr 24;422(6934):827-8. No abstract available.

PMID:
12712187
2.

Cancer research. Why some leukemia cells resist STI-571.

Marx J.

Science. 2001 Jun 22;292(5525):2231-3. No abstract available.

PMID:
11423629
3.

c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

Nagar B.

J Nutr. 2007 Jun;137(6 Suppl 1):1518S-1523S; discussion 1548S.

4.

Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival.

Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A.

EMBO Rep. 2005 Jan;6(1):63-9.

5.

The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.

Nicolini FE, Chabane K, Cayuela JM, Rousselot P, Thomas X, Hayette S.

Haematologica. 2006 Jan;91(1):137-8.

6.

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.

ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320.

PMID:
19039816
7.

Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J.

Cell. 2003 Mar 21;112(6):859-71.

8.

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J.

Mol Cell. 2006 Mar 17;21(6):787-98.

9.

Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.

Fujita A, Shishido T, Yuan Y, Inamoto E, Narumiya S, Watanabe N.

Mol Pharmacol. 2009 Jan;75(1):75-84. doi: 10.1124/mol.108.051706. Epub 2008 Oct 3.

10.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Ren R.

Nat Rev Cancer. 2005 Mar;5(3):172-83. Review.

PMID:
15719031
11.

Last findings on dual inhibitors of abl and SRC tyrosine-kinases.

Schenone S, Manetti F, Botta M.

Mini Rev Med Chem. 2007 Feb;7(2):191-201. Review.

PMID:
17305593
12.

Gleevec target Abl important for normal immune activation of T cells.

[No authors listed]

Cancer Biol Ther. 2004 Aug;3(8):704. No abstract available.

PMID:
15751157
13.
14.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

15.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
16.
17.

Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

Liu H, Li H, Feng Z, Tai J, Meng Y, Wang H, Xin H, Zhang S, Zuo M, Zhang Y, Chen X.

Leuk Lymphoma. 2009 Mar;50(3):437-46. doi: 10.1080/10428190802709438.

PMID:
19347730
18.

A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localization.

Henkemeyer M, West SR, Gertler FB, Hoffmann FM.

Cell. 1990 Nov 30;63(5):949-60. No abstract available.

PMID:
2175256
19.

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.

Grammatico S, Elia L, Peluso AL, Pedace L, Matarazzo M, Vitale A, Rago A, Pane F, FoĆ  R, Cimino G.

Leuk Res. 2009 Jul;33(7):e73-4. doi: 10.1016/j.leukres.2008.11.009. Epub 2008 Dec 23. No abstract available.

PMID:
19108887
20.

The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.

Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T.

Structure. 2005 Jun;13(6):861-71.

Supplemental Content

Support Center